妇科恶性肿瘤复发或寡转移根治性放疗后的长期生存:一项界标分析
对48例接受根治性放疗后生存≥5年的复发性或寡转移性妇科恶性肿瘤患者进行界标分析,中位随访11.7年,52%存活且无病,同步放化疗者中位无病生存期高于单纯放疗(93 vs 34个月,P=0.05),结论认为长期生存可能,但需随机数据确定最获益人群。
要点
- 48例根治性放疗后生存≥5年的复发性或寡转移性妇科恶性肿瘤患者中,52%存活且无病。
- 同步放化疗者中位无病生存期高于单纯放疗者(93 vs 34个月,P=0.05)。
- 中位随访11.7年时,23%出现疾病进展,42%死亡。
核心结论
- 接受根治性放疗的复发性或寡转移性妇科恶性肿瘤患者可能获得长期生存,但需要随机数据来确定哪些患者获益最大。
研究设计与样本
- 界标分析纳入48例接受转移灶根治性放疗后生存≥5年的复发性或寡转移性妇科恶性肿瘤患者,患者特征从病历中提取,无病生存期采用Kaplan-Meier法建模。
主要发现
- 队列包括卵巢癌20例(42%)、子宫内膜癌16例(33%)、宫颈癌11例(23%)、阴道癌1例(2%)。
- 复发性或寡转移部位为盆腔淋巴结(46%)、腹主动脉旁淋巴结(44%)、锁骨上淋巴结(7%)、纵隔淋巴结(4%)、腋窝淋巴结(4%)和肺(5.5%)。
- 中位放疗总剂量和分次剂量分别为62.1 Gy和2.1 Gy/次;1例接受立体定向体部放疗(SBRT)。
- 32例(67%)接受同步放化疗,其中位无病生存期高于单纯放疗者(93 vs 34个月,P=0.05)。
- 中位随访11.7年时,11例(23%)出现疾病进展;20例(42%)死亡,其中9例(19%)死于非妇科肿瘤,8例(17%)死于妇科肿瘤(3例未知)。
局限性
- 原文结论指出需要随机数据来确定哪些患者获益最大。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Radiation therapy (RT) may improve outcomes for patients with oligometastatic cancer. We sought to determine if there are long-term survivors treated with definitive RT for recurrent or oligometastatic gynecological cancer (ROMGC), and to evaluate the clinical and disease characteristics of these patients. METHODS: We performed a landmark analysis in 48 patients with ROMGC who survived for ≥5 years following definitive RT of their metastasis. Patient characteristics were extracted from the medical record. DFS was modeled using the Kaplan-Meier method. RESULTS: This cohort included 20 patients (42%) with ovarian cancer, 16 (33%) with endometrial cancer, 11 (23%) with cervical cancer, and one (2%) with vaginal cancer. The sites of ROMGC were the pelvic (46%), para-aortic (44%), supraclavicular (7%), mediastinal (4%), axillary (4%) lymph nodes and the lung (5.5%). Median total RT dose and fractionation were 62.1 Gy and 2.1 Gy/fraction; one patient was treated with SBRT. 32 patients (67%) received chemoradiation; these patients had higher rates of median DFS than those treated with RT alone (93 vs. 34 months, P = 0.05). At median follow-up of 11.7 years, 11 (23%) patients had progression of disease. 20 (42%) patients had died, 9 (19%) died from non-gynecologic cancer and 8 (17%) from gynecologic cancer (three were unknown). 25 (52%) patients were alive and disease-free (10 initially had endometrial cancer [63% of these patients], eight had cervical cancer [73%], six had ovarian cancer [30%], one had vaginal cancer [100%]). CONCLUSIONS: Long-term survival is possible for patients treated with definitive RT for ROMG, however randomized data are needed to identify which patients derive the most benefit.
引用
- Corrigan KL, Yoder A, De B, et al. Long-term survival following definitive radiation therapy for recurrence or oligometastases in gynecological malignancies: A landmark analysis. Gynecol Oncol. 2021. PMID: 34974906. doi:10.1016/j.ygyno.2021.12.022
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。